Company: Gilead Sciences
2018 U.S. sales: $3.63 billion
Used for: HIV
Two years after being touted as Gilead’s most successful launch, HIV single-tablet treatment Genvoya just keeps growing—and that's saying something, given its sister drug Biktarvy’s march to dominance.
Genvoya cleared $3.63 billion in U.S. sales for 2018, a roughly 20% increase over the previous year.
When Genvoya hit the market in early 2016, it was touted as one of Gilead Sciences’ best single-tablet launches and as the most-prescribed HIV drug targeting both first-line patients and those switching from other regimens. At the end of its first year on the market, Genvoya had cleared $1.3 billion in U.S. sales, an immediate blockbuster. By year-end 2017, those sales numbers had jumped to just over $3 billion.
And while that skyrocketing growth eventually slowed, Genvoya has maintained steady gains even as Gilead and GlaxoSmithKline continue to duel it out in the profitable field. Recently, GSK notched an FDA nod for its two-drug regimen Dovato, a combination of Tivicay and Epivir.
Biktarvy, Gilead’s recent single-tablet, three-drug treatment, could hit $6 billion in peak global sales, analysts have said, with some of that market share coming from Glaxo competitors—but also from Gilead’s own drugs.